右美托咪定与瑞芬太尼联合七氟烷在肝癌射频消融中的随机对照试验比较
结果显示两组术后疼痛、镇痛药用量、舒适度、肝功能及苏醒时间无差异,但右美托咪定组心率和七氟烷用量显著降低。结论认为低剂量右美托咪定可作为七氟烷麻醉下射频消融的安全辅助用药。
要点
- 右美托咪定组与瑞芬太尼组术后疼痛强度及镇痛需求无显著差异。
- 右美托咪定组插管后1分钟及手术开始30分钟后至麻醉恢复期间心率显著低于瑞芬太尼组。
- 右美托咪定组七氟烷浓度和用量显著低于瑞芬太尼组。
核心结论
- 低剂量右美托咪定可降低肝癌射频消融术中七氟烷用量和心率,不加重术后不适或肝功能障碍,可作为安全辅助用药。
主要发现
- 两组术后疼痛强度、镇痛药消耗、舒适度、肝功能及苏醒和拔管时间无差异。
- 右美托咪定组在插管后1分钟及手术开始30分钟后至麻醉恢复期间心率显著低于瑞芬太尼组,平均动脉压无显著差异。
- 右美托咪定组七氟烷浓度和用量显著低于瑞芬太尼组。
关键数值与推荐
- 右美托咪定组:麻醉诱导前15分钟开始给予负荷剂量0.4 μg kg-1,随后以0.2 μg kg-1 h-1持续输注至手术结束前10分钟。
- 瑞芬太尼组:麻醉诱导前15分钟至手术结束给予3 μg kg-1 h-1瑞芬太尼。
临床怎么用
- 在肝癌射频消融七氟烷麻醉中,可考虑使用低剂量右美托咪定作为辅助,以减少吸入麻醉药用量并控制心率。
局限性
- 分组分配对患者和数据分析人员设盲,但对麻醉医生未设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Remifentanil is widely used for ultrasound-guided percutaneous radiofrequency ablation (RFA) of small hepatocellular carcinoma (HCC). We determined whether dexmedetomidine could be an alternative to remifentanil for RFA of HCC under general anesthesia with sevoflurane. METHODS: We prospectively randomized patients scheduled to undergo RFA for HCC to a dexmedetomidine (DEX) group or remifentanil (REMI) group (47 patients each). In the DEX group, a bolus infusion (0.4 μg kg- 1) was started 15 min before anesthesia induction and continued at 0.2 μg kg- 1 h- 1 until 10 min before the end of surgery. In the REMI group, 3 μg kg- 1 h- 1 of remifentanil was administered from 15 min before anesthesia induction to the end of the surgery. The primary endpoint was postoperative pain intensity. Secondary endpoints included analgesic requirement, postoperative liver function, patient comfort, and hemodynamic changes. Group allocation was concealed from patients and data analysts but not from anesthesiologists. RESULTS: Postoperative pain intensity, analgesic consumption, comfort, liver function, and time to emergence and extubation did not differ between the two groups. Heart rate, but not mean arterial pressure, was significantly lower in the DEX group than in the REMI group, at 1 min after intubation and from 30 min after the start of the surgery until anesthesia recovery. Sevoflurane concentration and dosage were significantly lower in the DEX group than in the REMI group. CONCLUSION: During RFA for HCC, low-dose dexmedetomidine reduced the heart rate and need for inhalational anesthetics, without exacerbating postoperative discomfort or liver dysfunction. Although it did not exhibit outstanding advantages over remifentanil in terms of pain management, dexmedetomidine could be a safe alternative adjuvant for RFA under sevoflurane anesthesia. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-OPC-15006613 . Registered on 16 June 2015.
引用
- Pan J, Li X, He Y, et al. Comparison of dexmedetomidine vs. remifentanil combined with sevoflurane during radiofrequency ablation of hepatocellular carcinoma: a randomized controlled trial. Trials. 2019. PMID: 30621749. doi:10.1186/s13063-018-3010-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。